Insider Selling: Sight Sciences (NASDAQ:SGHT) Insider Sells $362,388.00 in Stock

Sight Sciences, Inc. (NASDAQ:SGHT) insider Jeremy Hayden sold 44,850 shares of the firm’s stock in a transaction that occurred on Tuesday, November 25th. The stock was sold at an average price of $8.08, for a total transaction of $362,388.00. Following the transaction, the insider directly owned 256,590 shares of the company’s stock, valued at $2,073,247.20. This represents a 14.88% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Sight Sciences Stock Down 0.5%

SGHT stock opened at $8.35 on Friday. The company has a market capitalization of $441.46 million, a P/E ratio of -9.28 and a beta of 2.47. Sight Sciences, Inc. has a 12 month low of $2.03 and a 12 month high of $8.80. The firm’s fifty day simple moving average is $5.15 and its 200-day simple moving average is $4.27. The company has a debt-to-equity ratio of 0.62, a current ratio of 9.60 and a quick ratio of 8.93.

Sight Sciences (NASDAQ:SGHT) last issued its earnings results on Wednesday, September 8th. The company reported ($0.81) earnings per share (EPS) for the quarter. Sight Sciences had a negative return on equity of 61.59% and a negative net margin of 60.63%.The business had revenue of $12.54 million for the quarter. As a group, equities research analysts forecast that Sight Sciences, Inc. will post -0.99 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts have recently commented on SGHT shares. Citigroup lowered their target price on Sight Sciences from $4.50 to $4.00 and set a “neutral” rating on the stock in a research note on Tuesday, October 7th. Wall Street Zen upgraded Sight Sciences from a “sell” rating to a “hold” rating in a research report on Saturday, September 13th. Needham & Company LLC reaffirmed a “hold” rating on shares of Sight Sciences in a research note on Thursday, August 28th. Piper Sandler lifted their target price on shares of Sight Sciences from $4.00 to $5.00 and gave the company a “neutral” rating in a report on Friday, November 7th. Finally, Morgan Stanley increased their price target on shares of Sight Sciences from $4.00 to $6.00 and gave the stock an “equal weight” rating in a report on Monday, November 10th. Three equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Sight Sciences presently has a consensus rating of “Hold” and an average price target of $5.17.

Institutional Trading of Sight Sciences

A number of institutional investors and hedge funds have recently made changes to their positions in the business. BNP Paribas Financial Markets lifted its position in shares of Sight Sciences by 99.8% during the 3rd quarter. BNP Paribas Financial Markets now owns 7,579 shares of the company’s stock valued at $26,000 after buying an additional 3,785 shares in the last quarter. CWM LLC lifted its holdings in Sight Sciences by 70.2% during the second quarter. CWM LLC now owns 7,607 shares of the company’s stock valued at $31,000 after purchasing an additional 3,137 shares in the last quarter. Tower Research Capital LLC TRC lifted its holdings in Sight Sciences by 32.7% during the second quarter. Tower Research Capital LLC TRC now owns 11,665 shares of the company’s stock valued at $48,000 after purchasing an additional 2,875 shares in the last quarter. Bank of Montreal Can acquired a new stake in shares of Sight Sciences in the second quarter valued at about $49,000. Finally, Vanguard Personalized Indexing Management LLC increased its stake in shares of Sight Sciences by 38.9% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 15,888 shares of the company’s stock worth $66,000 after purchasing an additional 4,453 shares in the last quarter. 55.51% of the stock is currently owned by hedge funds and other institutional investors.

Sight Sciences Company Profile

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.